- DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of rare bacteria selected by NAICONS.
- NAICONS has been convinced by the power of DEINOVE's robotic and integrated screening platform to rapidly identify and develop new antibiotics.
DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, announces that they have signed an exclusive research license with NAICONS to expand their current strain bank and increase the opportunities to discover new antibiotics.
The AGIR (Antibiotics against Resistant Infectious Germs) project, carried out by DEINOVE and its subsidiary DEINOBIOTICS, and supported by the Investments for the Future Program, aims to discover new antibiotics by systematically exploring the potential of the living world, and more specifically the great diversity of microorganisms. The project plans to rapidly and selectively enrich the collection of 6,000 rare bacterial strains of DEINOVE, in order to maximize the chances of discovery.
In addition to the collection of new strains in various natural environments, launched in 2017, DEINOVE has engaged a collaboration with the Italian biopharmaceutical company NAICONS, also specialized in the research for innovative antibiotics, which has a collection of 45,000 microbial strains.
As a first step, DEINOVE will have access to 400 strains carefully selected for their potential and will use the power of its robotic technology platform to detect and characterize the antibiotic activities of these strains. In case of discovery of a strain of interest, DEINOVE may acquire it (under the conditions provided for in this agreement) either via a commercial license or in full ownership, in order to initiate the development of drug candidates.
"We chose to open our rare bacteria collection to Deinove as part of an exclusive agreement because we are confident that they have the resources to discover antibiotics through their breakthrough technologies and the know-how of their team. Our collection can provide a larger number of antibiotics than we can discover with our own resources," said Stefano Donadio, CEO of NAICONS.
Emmanuel PETIOT, CEO of DEINOVE, said: "Our collaboration with Naicons is a good example of our antibiotics development model: this company historically rooted in the pharmaceutical sector has an interesting biological heritage which potential we can quickly explore, thanks to our reference platform. Joining forces to advance faster is essential to win the battle against the development of antibiotic resistance. This type of collaboration must be extended in the near future if we truly want to respond to this global public health threat."